A Phase 4 interventional study of adapalene/benzoyl peroxide and Topical Gel Vehicle in Acne, sponsored by Galderma R&D. Completed at 25 sites in 2 countries. Open to participants aged 9 Years to 11 Years. Per ClinicalTrials.gov, last updated 2021-02-18.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing adapalene in Acne Vulgaris — none open to participants now, 2 under way, none of them phase 3. Adapalene · Acne Vulgaris.
Among the 30 studies testing adapalene in Acne Vulgaris, this one is the 13th largest by enrollment, is one of 3 that started in 2010, is one of 11 in phase 4, and was the 11th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →None of the 30 studies testing adapalene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →
Adapalene: first FDA approval 1996 (DIFFERIN). What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 9 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 2 · Phase 3 9 · Phase 4 11
First in 2004; this study’s year is marked. 3 started in 2010.
This study's enrollment of 285 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 215 across the 30 interventional studies. Of the 26 that completed or were terminated, 16 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
49 studies in Acne Vulgaris by Galderma Group AG: none open now, 1 under way, 1 of them phase 3. Of 48 finished, 39 (81%) have results posted.
Among the 49 studies in Acne Vulgaris by Galderma Group AG, this one is the 18th largest by enrollment of the 46 interventional ones that give a count, is one of 6 that started in 2010, is one of 20 in phase 4, and was the 16th registered.
Galderma Group AG’s Acne Vulgaris studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 30 studies testing adapalene in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 49 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% administered once daily for up to 12 weeks in subjects 9 to 11 years of age with acne vulgaris.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% applied topically once daily for 12 weeks
Drug: adapalene/benzoyl peroxide
Topical Gel Vehicle applied topically once daily for 12 weeks
Drug: Topical Gel Vehicle
Drug pages: Adapalene · Benzoyl Peroxide
daily topical application for 12 weeks
Also known as: Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5%
daily topical application for 12 weeks
Success Rate
Percentage of subjects rated Clear or Almost Clear with at least 2 grades reduction from Baseline on the Investigator's Global Assessment (IGA)
Time frame: Baseline to Week 12 (Last Observation Carried Forward [LOCF])
Change From Baseline in Total Lesion Counts
Time frame: Baseline to Week 12 (LOCF)
Percent Change in Total Lesion Counts From Baseline
Time frame: Baseline to Week 12 (LOCF)
Change in Inflammatory Lesion Counts From Baseline
Time frame: Baseline to Week 12 (LOCF)
| Milestone | Adapalene/Benzoyl Peroxide | Topical Gel Vehicle |
|---|---|---|
| Started | 142 | 143 |
| Completed | 134 | 126 |
| Not completed | 8 | 17 |
Percentage of subjects rated Clear or Almost Clear with at least 2 grades reduction from Baseline on the Investigator's Global Assessment (IGA)
| percentage of participant | Adapalene/Benzoyl Peroxide | Topical Gel Vehicle |
|---|---|---|
| Success Rate | 47.2 | 15.4 |
| lesion count change | Adapalene/Benzoyl Peroxide | Topical Gel Vehicle |
|---|---|---|
| Change From Baseline in Total Lesion Counts | -27.6 ± 22.43 | -3.6 ± 24.44 |
| percentage of change in lesion count | Adapalene/Benzoyl Peroxide | Topical Gel Vehicle |
|---|---|---|
| Percent Change in Total Lesion Counts From Baseline | -55.5 ± 38.99 | -9.3 ± 48.00 |
| lesion count change | Adapalene/Benzoyl Peroxide | Topical Gel Vehicle |
|---|---|---|
| Change in Inflammatory Lesion Counts From Baseline | -7.4 ± 12.46 | -0.7 ± 12.46 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adapalene/Benzoyl Peroxide | — | 0/142 (0%) | 37/142 (26.1%) |
| Topical Gel Vehicle | — | 1/143 (0.7%) | 18/143 (12.6%) |
| Event | Adapalene/Benzoyl Peroxide | Topical Gel Vehicle |
|---|---|---|
| RIGHT FRONTAL ARTERIOVENOUS MALFORMATIONCongenital, familial and genetic disorders | 0/142 | 1/143 |
| Event | Adapalene/Benzoyl Peroxide | Topical Gel Vehicle |
|---|---|---|
| Skin burning sensationSkin and subcutaneous tissue disorders | 14/142 | 0/143 |
| NasopharyngitisInfections and infestations | 8/142 | 13/143 |
| Upper respiratory tract infectionInfections and infestations | 10/142 | 5/143 |
| Skin irritationSkin and subcutaneous tissue disorders | 8/142 | 0/143 |
| Age, Categorical(Participants) | Adapalene/Benzoyl Peroxide | Topical Gel Vehicle | Total |
|---|---|---|---|
| <=18 years | 142 | 143 | 285 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Adapalene/Benzoyl Peroxide | Topical Gel Vehicle | Total |
|---|---|---|---|
| Mean | 10.3 ± 0.76 | 10.4 ± 0.68 | 10.4 ± 0.72 |
| Sex: Female, Male(Participants) | Adapalene/Benzoyl Peroxide | Topical Gel Vehicle | Total |
|---|---|---|---|
| Female | 109 | 108 | 217 |
| Male | 33 | 35 | 68 |
| Region of Enrollment(participants) | Adapalene/Benzoyl Peroxide | Topical Gel Vehicle | Total |
|---|---|---|---|
| United States | 130 | 129 | 259 |
| Canada | 12 | 14 | 26 |
The record gives a start of Jun 2010, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2013, 1 year 7 months after primary completion. A results delay was requested in May 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Adapalene · Benzoyl Peroxide